cabozantinib,atezolizumab
exelixis,roche
[]
cabo+atz seems can overcome io resistance and has encouraging activity.#asco2022 
Professor, Head and Neck-Medical Oncologist, Neuro-Medical Oncologist, Thoracic-Medical Oncologist,Researcher,Immunotherapy, Statistics and Phase 1/2/3 studies